Silva Arslanian, ADA 2022: Dulaglutide for type 2 diabetes in youth, the AWARDS-PEDS study
The AWARDS-PEDS study assessed dulaglutide, a once-weekly subcutaneous injection of GLP-1 receptor agonist, in youth with type 2 diabetes and the key findings and implications are discussed by Dr Silva Arslanian (University of Pittsburgh, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA). The findings of this study come at a vital time, with type 2 diabetes at high levels amongst the youth, however, there are currently limited treatment options despite being a growing and progressive condition.
The abstract entitled ‘Dulaglutide in Youth with Type 2 Diabetes (T2D)—Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- What did the AWARD-PEDS study investigate? (0:21)
- What were the key findings for dulaglutide from AWARD-PEDS? (1:13)
- How can these findings support physicians in providing optimal support for young people with type 2 diabetes? (2:21)
Disclosures: Silva Arslanian is a consultant for and has received grant/research support from Novo Nordisk and Eli Lilly. Silva Arslanian is on the advisory board for the Data Monitoring Committee at AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Paediatric Endocrinology
Bradley Miller, ESPE 2022: Advantages of somapacitan versus daily GH in children with GH deficiency
Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the challenges of GH therapy in children and the […]
Bradley Miller, ESPE 2022: Once-weekly somapacitan versus daily GH in children with GH deficiency: The REAL 4 trial
The REAL 4 trial is a multicenter, randomized, controlled, double-blind phase 3 study (NCT03811535) to evaluate the efficacy, safety, and tolerability of once-weekly somapacitan vs once-daily growth hormone (GH). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the aims, design and results of the REAL 4 trial. The next […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!